A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients

NCT00002151 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Celgosivir hydrochloride

Sponsor

Hoechst Marion Roussel